baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Medicinova/ US58468P2065 /

20/05/2024 21:53:02	Chg. -0.06	Volume	Bid-	Ask-	High	Low
1.38USD	-4.17%	1 Turnover: 1.38	-Bid Size: -	-Ask Size: -	1.38	1.38

GlobeNewswire 20/05 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Preventio...

GlobeNewswire 14/05 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment...

GlobeNewswire 07/05 MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-1...

GlobeNewswire 03/04 MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Gliobla...

GlobeNewswire 27/03 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treat...

GlobeNewswire 21/03 MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentatio...

GlobeNewswire 12/03 MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung I...

GlobeNewswire 17/01 MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment...

GlobeNewswire 22/12/2023 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accep...

GlobeNewswire 07/12/2023 MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for t...

GlobeNewswire 20/11/2023 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Gliob...

GlobeNewswire 27/10/2023 MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment...

GlobeNewswire 11/10/2023 MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudi...

GlobeNewswire 05/10/2023 MediciNova Receives Gene Therapy Milestone Payment

GlobeNewswire 28/09/2023 MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medi...

GlobeNewswire 18/08/2023 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation...

GlobeNewswire 17/08/2023 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for ...

GlobeNewswire 16/08/2023 MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Scler...

GlobeNewswire 17/03/2022 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment ...

GlobeNewswire 15/03/2022 MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hos...

GlobeNewswire 28/02/2022 MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treat...

GlobeNewswire 22/02/2022 MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Diso...

GlobeNewswire 31/01/2022 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ba...

GlobeNewswire 27/01/2022 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for ...

GlobeNewswire 26/01/2022 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for H...

Medicinova/ US58468P2065 /

If you wish to receive reply to your feedback, please provide your email address.